Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II long-term extension of elsubrutinib and upadacitinib alone or in combination in moderate to severe active systemic lupus erythematosus
CTR20210600Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of upadacitinib, elsubrutinib in systemic lupus erythematosus (SLE), sponsored by AbbVie Inc.. Started Aug 2021; status: completed.
02
Drugs
upadacitinibelsubrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20210600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210600.